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Artificial Intelligence and Biotechnologyʼs Use in Health:
In Need of a Common Cure in Europe
Diogo COSTA CUNHA＊
“The development of full artificial intelligence could spell the end of the
human race.”1) Quoted Stephen Hawking, a globally renowned British physician,
about artificial intelligence on an interview to the BBC held on 1st of May 2014.
Other physicians such as Max Tegmark, Stuart Russell and Frank Wilczek share
his point of view.2)
On another hand, biotechnologies are perceived as unnatural, subject to fatal
errors, and possibly catastrophic for Humankind. One can fear a Human genome
irreversible degradation, biotechnological weapons leading to humankind self-
destruction etc. are fears one can have towards this flourishing technology.3)
Could we be facing two major apocalyptic and destructive technologies
leading towards the end of our civilisation? Reality may not be that Manichean, as
if the truth were that obvious research on both these domains would have been
stopped and declared forbidden well before meeting a market and being
commercialised. Therefore, there must be some good in these technologies that
balances humanityʼs feelings about them.
Following a long scientific development characteristic of the second half of
the 20th Century, these two technologies emerged in parallel. Even before they
were technologically achievable, they met in the foundational thoughts of
cybernetics where Louis Couffignal, a French mathematician, defined the machine,
yet in 1938 as “a consortium of unanimated or partially animated beings capable of
replacing mankind”.4) This definition does not exclude the conception of
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1) Rory Cellan-Jones, “Stephen Hawking warns artificial intelligence could end mankind”, BBC
News (2014) in : https://ww.bbc.com/news/technology-30290540 [28 October 2019].
2) Jean-Gabriel Ganascia, Le mythe de la Singularité. Faut-il craindre l’ intelligence
artificielle?, Le Seuil, 2017.
3) Gaëlle Le Dref, Théories de l’évolution et biotechnologies : d’une controverse à l’autre, PhD
thesis, (dir.) B. Ancori, (2017), Université de Strasbourg.
4) Bernard Claverie, “De la Cybernétique aux NBIC: l’information et les machines vers le →
“biological” machines, where the genes and their expressions are the pieces
constituting the whole machinery nor does it exclude the conception of
“immaterial” machines, where code lines replace genes. A unique definition defined
artificial intelligence and biotechnologies well before they both existed.
Tomorrowʼs technologies will likely disrupt the economy and society, as we
know it.5) The fourth industrial revolution gave rise to an exponential trend towards
the hyper-connection of society in all of its aspects: the objects of everyday
domestic life, as well as connected factoriesʼ means of production or connected
cities. Undeniably, health is also connected, the practice of medicine is being
transformed.6) It is precisely in this domain that the combination of biotechnology
and artificial intelligence shows its greatest innovative potential, as evidenced by
the, combination of the pharmaceutical and artificial intelligence industries.7)
The virtuous links between the two materials are very simple to understand.
Artificial intelligence makes it possible to establish more efficient diagnoses and
eliminates the human error factor; and biotechnologies produce inordinate volumes
of data, including gene-stored data, which are useful for the autonomous
development of artificial intelligence which can then help biotechnology
development creating a virtuous innovation loop. However, this data must be
legally exploitable. In that context, the regulatory role of legal standards on new
technologies must be taken into account first. The protection of personal data in
Europe is based on an endemic definition of property and privacy, which has its
legal roots in texts consented and adopted by European society.8)
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→ déplacement humain”, Hermès, la Revue, (2014), n° 68 pp. 95-101: “un ensemble d’êtres
inanimés ou partiellement animés capables de remplacer l’homme”.
5) Cheryl Martin et al., Readiness for the Future of Production Report 2018, World Economic
Forum’s System Initiative on Shaping the Future of Production, (2018) ; Jacques Lucas, “Le
médecin et le patient dans le monde des data, des algorithmes et de lʼintelligence artificielle”,
Innovations en santé publique, des données personnelles aux données massives (big data) :
aspects cliniques, juridiques et éthiques, (dir.) Christian Hervé et Michelle Stanton-Jean,
Dalloz, (2018), pp. 89-91.
6) Aicha Guelli, La médecine à l’ère de l’intelligence artificielle, PhD thesis, (dir.) M. Zouhdi,
(2018), Université Mohammed V - Rabat.
7) Lina Habbal, L’intelligence artificielle: nouveau levier de croissance pour les industries
pharmaceutiques, PhD thesis, (dir.) F. Devred, (2017), Université Aix-Marseille; Ivan
Capechi, “L’IA au service des médicaments de demain”, L’ADN, (2017), in https://www.ladn.
eu/nouveaux-usages/etude-marketing/comment-lia-va-permettre-de-creer-les-medicaments-de-
demain/ [28 October 2019]
8) Olivier Iteanu, Quand le digital défie l’État de Droit, Eyrolles, 2016.
This (over) protected data can be an obstacle to the development of Industry
4.0ʼs technologies, raising the imperative question of the role of the normative
framework in the regulation of artificial intelligence and biotechnologies.
Within which limits should the normative framework regulate the virtuous
development of new technologies, even though their consequences are uncertain. Is
the combination of artificial intelligence and biotechnology a sustainable process in
relation to health development: what are its limits?
The simultaneous use of biotechnologies and artificial intelligence in the
health domain creates a virtuous circle of innovation where each of them stimulates
the development of the other but normative framework is a double constraint to its
valorisation (I). However, the deregulation of the economic and legal normative
framework as such, is not enough to foster innovation, since the innovative duo
faces another constraint: social opposition supported by strong legal obstacles, as
the two technologies are among the toughest to be socially embraced (II).
I. A self-stimulating duo constrained by norms
The combination of two sectors with exponential innovative potential can only
be as mathematically successful as it is. Nevertheless, the comments concerning the
self-stimulation of artificial intelligence and biotechnologies must obviously be
tempered since these are still different sectors which only meet occasionally.
Indeed, scientific research, although based on a solid body of knowledge, is
nonetheless still carried out by subdivided scientific sectors, and within these
sectors themselves, there are subdivisions into sectors of applicability.9) Thus, in
many cases it is more relevant to approach a given topic from a specific angle of
applicability, to this instance human health. Likewise, with regard to the economy,
it is widely accepted that the meeting of innovative sectors is propitious for growth.
However, this growth can be based on the competition between several scientific
domains for the same market – each technology improving in order to respond to a
problem faced. Therefore, one of them can annihilate the other: leading to the end
of the research in one scientific discipline, and the appropriation of the
applicability domain by the other one,10) breaking the virtuous innovation circle of
simultaneous application.
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9) OECD Reviews of Innovation Policy: France 2014, OECD Review of Innovation Policy,
OECD (2014).
10) Jean-Luc Gaffard, “Concurrence et innovation en Europe: le dilemme de la compétitivité”,
OFCE, n° 102 (2017), pp. 353-379.
Such considerations cannot, in any way, jeopardize the fact that there is a
virtuous stimulating link, potentially durable if correctly supported, that arises from
the interaction between artificial intelligence and biotechnologies by using mutual
data (A), as well as a strong innovative potential.11) This link must undoubtedly be
valued, and the preferred instrument seems to be intellectual property – and more
specifically patents12) – and the options it provides (B), not without legal
boundaries.
A. The fragile simultaneous use throughout mutual data exploitation
New technologies when used simultaneously are part of a global innovation
context that is beneficial to their own growth as well as to global growth. This
hypothesis is empirically proven when applied to biotechnology and artificial
intelligence,13) two domains that at first glance would seem to opposed, but which
in reality were built on common ideas, and are equally useful in the field of
health.14)
It is therefore necessary to approach their relationship through the prism of the
health sector, particularly with regard to the development of artificial intelligence
using health data (1). In return, it would appear that artificial intelligence impact on
the biotechnology sector is broader and has repercussions on the entire scientific
research area (2).
1. Health data as a developer of artificial intelligence
According to INSERM (Institut National de la Santé Et de la Recherche
Médicale, French national research institute on health), there are six fields of
application of artificial intelligence in medicine: predictive medicine, precision
medicine, decision support, companion robots, computer-assisted surgery, and
prevention.15) Complementary to biotechnologies, which provide an efficient
treatment, the applications of artificial intelligence allow rapid diagnoses and
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11) Jacques Lucas, ibid., pp. 89-91.
12) Vincent Diebolt et al., “«Intelligence artificielle» : quels services, quelles applications, quels
résultats et quelle valorisation aujourdʼhui en recherche clinique? Quel impact sur la qualité
des soins? Quelles recommandations?”, Therapies, vol. 74, issue 1 (2019), pp. 141-154.
13) Lucie Cluzel-Metayer, “ LʼAssistance Publique-Hôpitaux de Paris : un «hôpital-entreprise» ?”,
RDSS, Dalloz, (2016), p. 1061.
14) Aicha Guelli, ibid.
15) INSERM - Jean Charlet, “Intelligence artificielle et santé : des algorithmes au service de la
médecine”, INSERM (2018), in https://www.inserm.fr/information-en-sante/dossiers-informa
tion/intelligence-artificielle-et-sante [29 october 2019].
appropriate treatment16) (surgical or biological).
Artificial intelligence is a complex technology with many facets and
variations. Among these, self-learning artificial intelligence relies on data analysis
for its success17). Three variables are thus necessary for its development: human
programming, computing power and data.18) If the first two cannot be linked to
the health domain, data analysis can be conducted on medical and genetic data.
There is a lot of health-related data, ranging from rare disease registries and
reactions to treatments, to the personal data collected by connected health devices
and inherent to persons. All these raw materials are undeniably useful for artificial
intelligence.
A particular application may be, for instance, the use of deep learning
software to detect melanomas in skin photos, or detect diabetic retinopathies before
they are incurable, and automatically decide on the appropriate treatment.19) In
some cases, such as the use of the artificial intelligence IBM Watson, they are even
able to cross-reference patient data with all the published – and constantly updated
– scientific data and make a diagnosis based on considerable amounts of medical
discoveries.20) The development of such systems requires a prior analysis of a large
amount of genuine medical data, which is described as sensitive data and may be
difficult to exploit. In the hypothetical context of a machine capable of detecting a
disease, it is obviously essential that the machine is networked and capable of
cross-referencing its data with other machines all over the world: learning is done
through mass experiencing. However, once these machines and the personal data
they use are released passed the research boundaries, they are no longer part of a
scientific research but are in fact used commercially by the entity making them
available and selling or exploiting them. Therefore, in this situation, an excessive
protection of health-related data would inevitably lead to a loss of performance for
such technologies.
The solution then seems to be data anonymization; keeping only two variables
in the example of skin photo analysis. The photograph itself, and the associated
response “infected”/“healthy”. In this way, the machines can continue to improve
without compromising patientsʼ privacy and the dataʼs use and commercialisation.
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16) Yves Poullet, “Le droit face aux développements de lʼintelligence artificielle dans le domaine
de la santé” (part. 1), RLDI, n° 152, (2018), § 3.
17) Jean-Gabriel Ganascia, ibid.
18) Yves Poullet, ibid., § 1.
19) INSERM - Jean Charlet, ibid.
20) Aicha Guelli, ibid.
In order to perfectly function the photograph in question must not indeed be
considered as personal data, not leading to the identification of an individual,
which seems to be the approach taken by the General Data Protection Regulation
(GDPR) in its Article 4.21) This means the data would have to remain isolated and
as such.
However, the main strength of artificial intelligence use in the medical field is
in the personalisation and cross-referencing of data relating to a particular
individual. For instance, there are specialised programs in patient data mining that
establish a risk probability and adapt treatments to their medical situation,22) and
even according to their lifestyle.23) It is therefore easy to understand that the
difficulty here is the possible identification of the patient as an individual, and thus
the qualification as “personal data”. Although this identification were to be
encrypted, it can be argued that the data remains “identifiable” in the sense of the
GDPR.24) Even though this qualification were not retained, the mere requirement of
strong and costly security measures protecting this data on the users and their
potential liability in the event their system fails is sufficient to weaken their
willingness to act, unless the sanctions are lower than the potential gain. However,
it is equally easy to understand that the protection of such data is essential for
patients,25) who could suffer serious consequences if such data were to come into
the hands of third parties, particularly insurance companies.
Thus, it is established that the use of data is beneficial to the development of
artificial intelligence in this sector. However, this data must still be able to be
freely exploited without legal obstacles, without undermining the peculiar
European concept of privacy,26) which is the first limit to the virtuous development.
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21) Article 4 (1), (13), (14), (15), Regulation (EU) 2016/679 of the European Parliament and the
Council of 27 April 2016 on the protection of natural persons with regard to the processing
of personal data and on the free movement of such data, and repealing Directive 95/46/EC
(General Data Protection Regulation), OJUE, (2016).
22) INSERM – Jean Charlet, ibid.
23) Yves Poullet, ibid., § 3.
24) Article 4 (1), Regulation (EU) 2016/679 of the European Parliament and the Council of 27
April 2016 on the protection of natural persons with regard to the processing of personal data
and on the free movement of such data, and repealing Directive 95/46/EC (General Data
Protection Regulation), OJUE, (2016).
25) Shane OʼSullivan et al., “Legal, regulatory, and ethical frameworks for development of
standards in artificial intelligence (AI) and autonomous robotic surgery”, Int. J. Med.
Robotics Comput. Assist. Surg, vol 15, issue 1 (2019).
26) Olivier Iteanu, ibid.
A balance therefore remains to be established between common progress and
individual freedom. On the other hand, it should be stressed that the simultaneous
development of the two technologies is also and more widely beneficial to the
development of biotechnologies, the complexity of which can be clarified by the
assistance of artificial intelligence.
2. Artificial Intelligence as an assistant of biomedical research
The use of biotechnology in health is complex and composed by several
techniques ranging from genetic modification to enzymatic treatment. Biological
research is intricate and expensive. Like any scientific research, it involves the
formulation of a hypothesis and its validation through an experiment. One cannot
discover a truth one can only invalidate a lie: that is the essence of scientific
reasoning. Artificial intelligence invalidates multiple lies faster than any man
does.
Artificial intelligence has already proved its worth in the field of biological
research, particularly in studies on cell mutation linked to neurodegeneration.27)
This application, based on the analysis of microscope images, is controlled by an
automatic artificial intelligence which improves with use in order to detect flawed
samples.
Nevertheless, this research support cannot stop there. It is then possible to
imagine, as soon as the legal limits related to data analysis are lifted, an artificial
intelligence that will analyse genetic data by crossing them with given empirical
data. It would be possible to establish a correlation between a gene and its
expression, or to observe and understand the functioning of the genome using self-
taught software or help to discover the relation between genetics and illnesses.28)
This use would allow researchers to save considerable time on their research by
reducing the scope of their hypotheses with respect to the correlations established
by automatic data analysis, and would allow laboratories to reduce their research
costs.29) Once again, the limits of the European limitations on personal data – either
social or legal – will undeniably be a limit to such development.
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27) LʼAtelier BNP-Paribas, “Lʼintelligence artificielle au service de la biologie”, BNP-Paribas
(2012), in: https://atelier.bnpparibas/smart-city/article/l-intelligence-artificielle-service-biologie
28) Davide Cirillo et al., “Big data analytics for personalized medicine”, Current Opinion in
Biotechnology, n° 58, (2019), pp. 161-167.
29) Lincoln Tsang, Daniel A. Kracov, Jacqueline Mulryne, Louise Storm, Nancy Perkins,
Richard Dickinson, Victoria M. Wallace and Bethan Jones, “The impact of Artificial
Intelligence on Medical Innovation in the European Union and United States”, Intellectual
Property & Technology Law Journal, Vol. 29 Issue 8, (2017), pp. 12-20.
This point of view is further understandable when taking into consideration
the risks and impacts of data crossing, and more specifically when it implies
ethnicities or social groups or communities associated with religious beliefs. A
simple empirical link between a disease, or a gene malfunction and a social group
– leading therefore to a difference of treatment from insurance companies for
instance – would not be permissible in light of the European fundamental rights
and equality principles, which find their sources in the highest supra-legislative
norms whether they be International Treaties or national Constitutions. Even
though no “personal” identification as such occurs, a “group” identification – or
even worse “classification” – would not be possible although scientifically proven.
The European legal regulations refuse to choose between risks on the one
hand – to their patients on behalf of individual protection – and innovation on
another hand – which leads to better standards of life when wisely developed
throughout economic growth. Still risk and innovation are the two faces of the
same coin,30) and finding the equilibrium so it can stay on its edge is not easy.
However, a step towards this balance needs to be highlighted on the data mining
exception adopted by the European Union throughout articles 3 to 7 of the
Directive on copyright and related rights in the Digital Single Market,31) which
helped to surpass the other limit on data use that was copyright. Maybe scientific
and medical exceptions could be an option the European Union should explore.
It is therefore demonstrated that the virtuous relationship between artificial
intelligence and biotechnology is highly beneficial and produces positive
externalities for research and innovation. Nevertheless, this momentum can be
broken if researchers cannot benefit from their work. The two technologies must be
mutual assistants in each otherʼs developments, and tools made available to
researchers to promote innovation, particularly with regard to health. This
innovation that must be able to be enhanced by intellectual property tools.
B. Valorisation by Intellectual Property tools
Intellectual property rights are key elements in the promotion of scientific
research. The mere granting of a patent, or any other instrument conferring a
monopoly, allows the research carried out to be made profitable and the innovation
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30) Patrick Perreti-Watel, “Risque et innovation: un point de vue sociologique”, Innovations
2003/2 n° 18, (2003), pp. 59-72.
31) Directive (EU) 2019/790 of the European Parliament and of the Council of 17 April 2019, on
copyright and related rights in the Digital Single Market and amending Directives 96/9/EC
and 2001/29/EC, OJEU, (2019), articles 3 and 7.
to be diffused in exchange for compensation on its discovery. However, the logic
of old intellectual property instruments comes up against its own limits when
confronted with new technologies such as artificial intelligence or biotechnology.
Indeed, artificial intelligence is software, and for the vast majority (excluding
robots) it is dissociated from particular machines. The patentability of artificial
intelligence as such is, in fact, very difficult if we follow the logic of intellectual
property law.32) In addition, artificial intelligence is protected by copyright, which
may be transferable in its economic provisions. But patent protection can also
protect the technical invention resulting from the software and not only the
software as such.33) Yet patenting an artificial intelligence, although done in
practice, is criticized since it involves the exploitation of a legal loophole and
should not occur as expressly prohibited by law on the patentability of software as
such in the spirit of European intellectual property.34) Furthermore, when dealing
with medical inventions, the European Patent Convention states that “diagnostic
methods practised on the human (…) body”35) are not patentable, adding another
limit to the patentability of artificial intelligence regarding medical applications and
therefore its valorisation.
Similarly, the exploitation of biological technologies by intellectual property
law instruments is just as sensitive since it raises the question of whether it is
possible - and to what extent - to patent living organisms. With regard to
inventions resulting from essentially biological processes, there is a specific
intellectual property title, the Plant Variety Certificate; but for inventions resulting
from non-plant living organisms the question of patentability is tricky. In reality,
discoveries, natural creations, are not protectable as they did not generate any effort
of invention from the researcher. Nonetheless, fundamental research is essential,
but it is difficult to value it through intellectual property rights - hence the
importance of state support. This is why living organisms cannot in principle be
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32) Jean-Marc Deltorn, “La brevetabilité des applications de lʼintelligence artificielle et de
lʼapprentissage automatique: la pratique de lʼOffice européen des brevets”, Propriété
industrielle, n° 3, doss. 4, (2019).
33) Jean-Marc Deltorn, ibid.
34) Article 52 (2) (c), European Patent Convention, as amended since its 16th edition, June 2016;
article L611-10 (2) (c), French Intellectual Property Code, as amended by law n° 2008-776,
(2008); article 4 (4) (c), Ley 24/2015, de 24 de julio, de Patentes (Spain), BOE n. 177,
(2015); section 1 (3) (c), Patentgesetz (Germany), as amended by act of 8 October 2017,
BGBI. I S. 3546, (2017).
35) Article 53 (c), European Patent Convention, ibid.
patented. However, the patentability of individual elements is possible under
Directive 98/44/EC of the European Parliament of 6 July 1998,36) provided that it
meets the general conditions of patentability and that it is an individual element for
industrial application concretely set out in the claims. The isolated nature is
essential as its state allows human intervention to be justified: from the technical
processes isolating it, a different state is created from the one in which it occurs in
nature.37) In addition to the technical limits, the patentability of living organisms is
also hampered by ethical limits, thus prohibiting the patentability of human
embryos, among others.38)
Naturally, the combined use of these two technologies is subject to the legal
limits of both. Consequently, there are only two ways for researchers wishing to
protect their inventions: circumventing legislation by patenting on a different
argument, or finding an alternative.
The alternative to Intellectual Propertyʼs valorisation would therefore be the
valorisation by social acceptation. Diffusing the innovation in order to create a new
market throughout the prism of a new created social need. However, this solution
is also bounded by another limit that are the ethical regulations especially hard
when dealing with health, or biotechnology and artificial intelligence.
This leads to well-defined limits to the valorisation of joint development
through intellectual property rights. The barriers to both are an additional difficulty
to overcome, but the legal standard has the duty to ensure the comfort of the
researchers using them. However, the facility of protection provided to researchers
must be balanced with the social interest and the rights of third party beneficiaries -
or not - from the innovation. It is difficult to predict the technological impacts and
therefore the legal limits.
II. The social acceptation of the innovation: ethical regulations
Legal limits on innovation are only imposed as a result of the societal will
through which it is created. Law is - in theory and without taking into account
certain nuances - a representation of a peopleʼs will that produces it. This is the
Social Contract as mentioned by Rousseau in the 18th century. Even if there were
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36) Directive 98/44/CE of the European Parliament and of the Council of 6 July 1998 on the
legal protection of biotechnological inventions, OJEC, (1998), article 5.
37) Béatrice Ores, Fabienne Paris and Lionel Vial, La brevetabilité du vivant, CNCPI, (2015),
déc.
38) CJUE, 18 October 2011, C-34/10 Olivier Brüstle v. Greenpeace eV, Christian Byk, JDI
(2013); Hélène Gaumont-Prat, Propriété industrielle, (2011), n˚ 6, p. 6, n 42.
to be a softening of the rules in favour of innovation, some inventions, innovations
and research could not be accepted since they did not correspond to the needs of
the sovereign majority at the moment they were created. Innovation is not
necessary, it is proposed then accepted. Yet, artificial intelligence and
biotechnology are oddly enough two technologies that meet a plethora of social
needs, but which are paradoxically mistrusted by consumers.39)
That is where information is central. It is the responsibility of legal standards
not only to protect the suspicious consumer, but also to ensure that they are offered
remedies by stimulating innovation. Over-regulation through ethics is only an
unbalanced inhibitor of innovation. (A) Indeed, innovation in the health sector,
among other things, by merging the sectors of artificial intelligence and
biotechnology, is too important to be simply rejected. (B)
A. Ethical and preventive regulations: an innovation inhibitor
Research on the human body is limited by legal norms that protect not only
the body but also the integrity of the person to whom it belongs. This protection is
also in the general interest: forbidding human enhancement and suffering human
beings as the result of poorly supervised experiments, experiments or scientific
attempts carried out by persons either malicious or not willing to pursue an
objective of real improvement of human life. The legal framework for
biotechnological research is a general interest protection in the personal interest of
the holders of new biotechnologies, creating an essential need.
However, at an early research stage, it is impossible to distinguish which
technologies will be potentially destructive from those that will be potentially life
saving. The Oviedo Convention - signed and ratified by a majority of Council of
Europe member states with the significant exception of Austria, Belgium, Germany,
Ireland, the United Kingdom and the European Union - formally prohibits the
violation of human integrity. It is therefore legally prohibited to carry out genetic
selection, gene therapies modifying the germ line, or the profitable use of human
material. These are laudable objectives in that they value the primacy of the human
being. According to Article 2 of the Oviedo Convention, “the interest and welfare
of the human being shall prevail over the sole interest of society or science”40). But
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39) Mady Delvaux, Report with recommendations to the Commission on Civil Law Rules on
Robotics (2015/2103 (INL)), Committee on Legal Affairs, European Parliament, Plenary
sitting, 27 January 2017.
40) Convention for the Protection of Human Rights and Dignity of the Human Being with regard
to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine, →
this is a principle whose application becomes impossible when pushed to its limits.
Indeed, the interest and well-being of a person may depend on the use of genetic
material or research carried out on another; this is a philosophical bias responding
to the historical consequences of experiments during and after the Second World
War, with complicated legal application.41) The same philosophical issues arise
when dealing with artificial intelligence,42) even though no international treaty rules
these uses yet, arising thus the question of human security against it.
European Union law has also addressed bioethics and medical research issues.
This may seem surprising in that these are provisions resulting from the application
of fundamental rights and therefore traditionally dealt with by the Council of
Europe, but as previously demonstrated, the health market is necessarily social,
political and economic, and in its prerogatives are necessarily affected by European
Union law. The European Union based its legal actions on the basis of the Charter
of Fundamental Rights. The provisions of Article 3 of the Charter43) are essentially
the same as those of the Oviedo Convention. They consist of a main principle: the
informed consent of the subjects; and three prohibitions: the prohibition of
eugenics, the prohibition of taking advantage of the human body, and the
prohibition of reproductive cloning. The informed consent of the patient is also
needed while using health data; complicating their use as previously demonstrated.
Furthermore, the prohibition of article 3 (2) (c) “on making the human body and its
parts as such a source of financial gain”44) could be a supplementary boundary
when dealing with genetics if one considers that genetic information encoded in
DNA is a part “as such” of the human body. Ethical considerations on behalf of
Human Rights jeopardise scientific research and valorisation.
However, this framework is an untouchable consequence of fundamental
rights, but not a fundamental rights issue itself. It is an interpretation of these rights
that is subject to change. Indeed, the question of biomedical research and its
applications cannot have a restricted dual answer saying authorisations or
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41) Anne Laude, “La réforme de la loi sur les recherches biomédicales”, Dalloz, (2009), p. 1150,
§ 2.
42) Shane OʼSullivan et al., “Legal, regulatory, and ethical frameworks for development of
standards in artificial intelligence (AI) and autonomous robotic surgery”, Int. J. Med.
Robotics Comput. Assist. Surg, vol 15, issue 1 (2019).
43) Charter of Fundamental Rights of the European Union (2012/C 326/02), OJEU, (2012),
article 3 (2).
44) Charter of Fundamental Rights of the European Union, ibid.
prohibitions; it must necessarily be based on a free research principle, and framed
by ethical authorities in order to maintain a balance between effective research and
its benefits, and the protection and application of irrevocable fundamental rights.
This is why the legislative framework should be permissive and adapted in the
context of research.
It is therefore easy to see that ethical regulation preventing the drifts of
innovation creates a barrier sometimes impassable, for the desirable innovation
needed among the masses. This inadequate filter can have the first effect of
aborting innovation, and paradoxically, of encouraging unethical innovation at the
international level by opening up the possibility of a profitable monopoly for
foreign competitors.
B. Towards a new definition of innovation?
As it stands, science allows a great understanding of genetics. However, it is
not the understanding, but the possible and future actions that are already available
that are subject to research today. Although one cannot exist without the other, it is
possible to note a turning point in the scientific literature, but also in the
information field: there is uncertainty and division about the future application of
biotechnology and, in the same way that artificial intelligence - which has been
around for years - nowadays arouses many fantasies, they are attracting scientific
interest. Indeed, the combined use of both this almost science fiction technology,
shall be the solution to incurable diseases - among other industrial applications -,
which piques the interest of the economic sector45). A change, or even creation, of a
new market is emerging and its structural changes are already underway.
The economic domain evolves in correlation with the scientific domain
according to the application sector of the technologies resulting from it. Only from
their union can innovation be born. Indeed, it has multiple definitions: it can be
from an economic point of view perceived as “the successful marketing of a new
product, process or service”46), but also from an internal point of view to innovation
actors as “everything that is new for the company, which allows it to acquire a
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45) Isabelle Poirot-Mazères, “Robotique et médecine: quelle (s) responsabilité (s)?”, Journal
international de bioéthique, vol 24, n° 4, (2013), pp. 99-124; Filippo Pesapane, Marina
Codari et al., “Artificial intelligence in medical imaging: threat or opportunity? Radiologists
again at the forefront of innovation in medicine”, European Radiology Experimental, 2:35
(2018).
46) Thierry Lucidarme, Valoriser et développer l'innovation, Vuibert, (2013), p. 206 “la mise sur
le marché réussie dʼun produit, procédé ou service nouveau”.
sustainable competitive advantage in response to a market need.”47) Innovation is an
invention that has become a reality. Invention which itself is a “discovery in the
field of the mind”48).
Thus, science - discoveries of the world - and innovation - the concretisation
of discoveries of the mind - are intimately linked. Indeed, it is the discoveries of
the physical world resulting from observations that give the necessary knowledge
to the discovery of the mind which is acheived by the meeting of a market. This
gives rise to a chronological axis that cannot be ignored in the innovation process:
research, invention, meeting a market. Innovation is the process by which scientific
discovery is transformed into a market product.
This logic is also found in intellectual property, where the patent is only the
title that guarantees the protection of industrial application and not scientific
discovery. The patent protects industrial application and not innovation, invention
nor discovery49). The patent is then the legal tool that serves the economy in its
quest to meet a market. This is why it would seem that innovation is governed only
by the economy and the willingness of economic agents to value their intangible
assets for profit. Scientific and legal instruments are only tools in an economic
process.
The possibility of future commercialization then relegates research to the rank
of economic investment, which is then given a certain importance and - to a certain
extent - financial value. Indeed, at the same time, the economy is a driving force, a
tool, a research tool and therefore at the service of scientific discovery. In the same
way that Man and Nature are a tangle of causes and consequences, so are science
and economics.
The valorisation is made by the fusion of technologies as well, therefore
certainly by the construction of multi-technology parks and the communication of
knowledge beyond the materials in which they were acquired. It is up to the legal
world to ensure the right mix of innovative sectors by stimulating the positive
aspects and limiting uncontrolled and therefore potentially dangerous innovation.
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(2013), pp. 83-88 “tout ce qui est nouveau pour lʼentreprise, qui permet dʼacquérir un
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